106 related articles for article (PubMed ID: 29783891)
1. Increased DHRS12 expression independently predicts poor survival in patients with high-grade serous ovarian cancer.
Zhang Y; Wu J; Jing H; Huang G; Dong J; Cui Z
Future Oncol; 2018 Oct; 14(25):2579-2588. PubMed ID: 29783891
[TBL] [Abstract][Full Text] [Related]
2. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
He J; Liu Y; Zhang L; Zhang H
Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
[TBL] [Abstract][Full Text] [Related]
3. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
4. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
5. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
6. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
9. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
10. PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.
Lohneis P; Darb-Esfahani S; Dietel M; Braicu I; Sehouli J; Arsenic R
Anticancer Res; 2015 Nov; 35(11):6329-34. PubMed ID: 26504072
[TBL] [Abstract][Full Text] [Related]
11. A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas.
Mittal K; Choi DH; Klimov S; Pawar S; Kaur R; Mitra AK; Gupta MV; Sams R; Cantuaria G; Rida PCG; Aneja R
J Ovarian Res; 2016 Mar; 9():17. PubMed ID: 26992853
[TBL] [Abstract][Full Text] [Related]
12. CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro.
Paatero I; Lassus H; Junttila TT; Kaskinen M; Bützow R; Elenius K
Gynecol Oncol; 2013 Apr; 129(1):179-87. PubMed ID: 23313737
[TBL] [Abstract][Full Text] [Related]
13. HSP60 predicts survival in advanced serous ovarian cancer.
Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Int J Gynecol Cancer; 2013 Mar; 23(3):448-55. PubMed ID: 23429486
[TBL] [Abstract][Full Text] [Related]
14. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
15. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
Roy M; Connor J; Al-Niaimi A; Rose SL; Mahajan A
Hum Pathol; 2018 Mar; 73():1-6. PubMed ID: 28851663
[TBL] [Abstract][Full Text] [Related]
17. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.
Zheng M; Mullikin H; Hester A; Czogalla B; Heidegger H; Vilsmaier T; Vattai A; Chelariu-Raicu A; Jeschke U; Trillsch F; Mahner S; Kaltofen T
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271935
[TBL] [Abstract][Full Text] [Related]
19. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
20. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
